Baxter's Fourth Quarter Performance Overview
Baxter delivered a fourth-quarter adjusted EPS of 44 cents, which unfortunately fell short of the management’s guidance of 52-57 cents, and also did not meet Wall Street’s expectation of 54 cents. This decline in earnings was primarily attributed to an unfavorable product mix.
Sales Figures and Growth
The medical device manufacturer reported impressive sales figures of $2.974 billion, marking an 8% increase year-over-year. On an operational basis, the growth stood at 3%, surpassing the consensus which anticipated sales of $2.824 billion.
Interestingly, management had expected fourth-quarter sales growth to be around 2% on a reported basis while anticipating a slight decline of about 2% operationally.
Segment Analysis
Medical Products & Therapies
In the segment of Medical Products & Therapies, sales reached approximately $1.39 billion, reflecting a 6% increase on a reported basis and 4% operationally. This growth can be attributed to the rising demand from the Infusion Therapies & Technologies division, particularly driven by robust performance in IV solutions.
Healthcare Systems & Technologies
Sales in Healthcare Systems & Technologies amounted to $827 million, indicating a growth of 5% on a reported basis and 4% operationally. This positive outcome is largely due to high demand for Care & Connectivity Solutions alongside growth within the Front Line Care division.
Pharmaceutical Sales
Pharmaceutical sales saw a total of approximately $668 million, which represents a 4% growth on a reported basis and 2% operationally. This performance was buoyed by sustained strength in Drug Compounding, although this was slightly mitigated by decreased sales in Injectables & Anesthesia.
“Despite delivering sales growth across all segments, our fourth-quarter results did not align with our expectations,” stated Andrew Hider, Baxter's president and CEO. He emphasized the company’s ongoing dedication to improving performance through a recently introduced operating model aimed at simplifying the organization and fostering innovation.
Guidance for 2026
Looking ahead, Baxter has projected its fiscal 2026 adjusted earnings to fall within the range of $1.85-$2.05 per share. This guidance stands in contrast to the consensus estimate of $2.25.
Adjusted operating margins are anticipated to be between 13% and 14%, showcasing the company’s commitment to maintaining a healthy financial structure during challenging times.
The hospital product manufacturer expects sales for 2026 to range between $11.24 billion and $11.36 billion, slightly above the consensus estimate of $11.31 billion. Furthermore, Baxter forecasts a flat sales growth projection for 2026, with an increase of up to 1% expected.
BAX Stock Performance
In terms of stock performance, Baxter’s shares experienced a notable decline of 15.6%, trading at $18.79 at the time of this report. This decline has brought the stock near its 52-week low of $17.4, as indicated by recent data metrics.
Frequently Asked Questions
What were Baxter's adjusted EPS figures for the fourth quarter?
Baxter reported an adjusted EPS of 44 cents for the fourth quarter.
How much did Baxter's sales increase year-over-year?
Baxter's sales increased by 8% year-over-year, totaling $2.974 billion.
What is Baxter's projected adjusted earnings for fiscal 2026?
Baxter expects adjusted earnings between $1.85 and $2.05 per share for the fiscal year 2026.
What is the anticipated sales growth for Baxter in 2026?
Baxter projects sales growth in 2026 to remain flat to an increase of 1%.
How did Baxter's stock perform recently?
Baxter's stock fell by 15.6%, trading at $18.79, close to its 52-week low of $17.4.
